期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.680503
关键词
radiation; radiotherapy; targeted radionuclide therapy; inflammation; nucleic acids; bystander immunity; cGAS; STING
类别
资金
- SIRIC Montpellier Cancer Grant [INCa_Inserm_DGOS_12553]
- INCa-Canceropole GSO
- AVIESAN PCSI [ASC20025FSA]
Radiation therapy has transitioned into the era of personalized medicine in the past decade, but the challenge now lies in identifying the optimal radiation regimen to induce a clinically relevant anti-tumor immune response. Organs at risks and tumor microenvironment components often limit the effectiveness of radiation therapy, highlighting the importance of understanding immune response in tumor control and treatment optimization.
In the past decade, radiation therapy (RT) entered the era of personalized medicine, following the striking improvements in radiation delivery and treatment planning optimization, and in the understanding of the cancer response, including the immunological response. The next challenge is to identify the optimal radiation regimen(s) to induce a clinically relevant anti-tumor immunity response. Organs at risks and the tumor microenvironment (e.g. endothelial cells, macrophages and fibroblasts) often limit the radiation regimen effects due to adverse toxicities. Here, we reviewed how RT can modulate the immune response involved in the tumor control and side effects associated with inflammatory processes. Moreover, we discussed the versatile roles of tumor microenvironment components during RT, how the innate immune sensing of RT-induced genotoxicity, through the cGAS-STING pathway, might link the anti-tumor immune response, radiation-induced necrosis and radiation-induced fibrosis, and how a better understanding of the switch between favorable and deleterious events might help to define innovative approaches to increase RT benefits in patients with cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据